Diagnostic firm MicrosensDx is working with The Mayr Group at Imperial College London to develop a novel biomarker test for the early recognition of sepsis. Based on MicrosensDx’s IP and technology, and designed to fit with existing diagnostic processes, this test could potentially fill a critical gap in patient management, offering clinicians a specific, quantitative diagnostic and prognostic solution to help prioritise appropriate treatment of sepsis.
Features
Whooping cough, the resurgence of a vaccine preventable disease
Dr Neil Bentley looks at the history, causes and treatment of whooping cough, as well as examining the vaccine issues which may have contributed to a recent resurgence of the condition in many countries around the world.
Putting patients at the heart of phlebotomy booking services
Warrington and Halton Teaching Hospitals NHS Foundation Trust has transformed the service it offers to GPs and patients for phlebotomy appointments by deploying two key innovative technologies that make the whole process paperless.
Latest Issues
The laboratory business is under pressure to change. Market consolidation, standardisation, advanced automation, genomic testing, and the increase in point-of-care testing are driving major shifts in where, when, and how testing takes place. To not only survive, but to thrive, laboratories need a new generation of informatics solutions with...
Microbe Conference 2024
Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024
Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities
Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024
The British Association for Cytopathology Annual Scientific Meeting
Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024
UK NEQAS: Navigating Quality Standards in Point of Care Testing
The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024
Medica
Messe Dusseldorf
11-14 November, 2024